Floatz logo

Cynk-001

Neoplasm, Plasma Cell

Celularity IncorporatedCell therapyPhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Neoplasm, Plasma Cell cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BBB
cc-5013
Hellenic Society of Hematology
Phase 3BBB
Cyclophosphamide
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Fludarabine
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Fludarabine
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

Cynk-001 is also rated in:

giant cell glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
glioblastomaDormant
C
Indicative ·
37 / 100
View asset →
monoclonal paraproteinemia diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →